Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/27311
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2030-01-01
Colecciones
- INI - Artigos de Periódicos [3397]
- IOC - Artigos de Periódicos [12500]
Metadatos
Mostrar el registro completo del ítem
NEVIRAPINE CONCENTRATIONS IN NEWBORNS RECEIVING AN EXTENDED PROPHYLACTIC REGIMEN
Recém-nascido
Nevirapina
Farmacocinética
Autor
Afiliación
Boston University School of Medicine. Department of Pediatrics. Boston, MA, USA.
David Geffen University of California Los Angeles School of Medicine. Department of Pediatrics. Los Angeles, CA, USA.
Hospital Geral de Nova Iguaçu. Departamento de Doenças Sexualmente Transmissíveis. Nova Iguaçu, RJ, Brasil.
Universidade Federal de Minas Gerais. Departamento de Pediatria. Belo Horizonte, MG, Brasil.
San Juan City Hospital. Department of Pediatrics. San Juan, PR.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ. Brasil.
Johns Hopkins University. Division of Clinical Pharmacology. Baltimore, MD, USA.
National Institute of Child Health and Human Development (NICHD) / National Institutes of Health. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.
National Institute of Child Health and Human Development (NICHD) / National Institutes of Health. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.
National Institute of Child Health and Human Development (NICHD) / National Institutes of Health. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.
Westat, Inc., Rockville. MD, USA.
David Geffen University of California Los Angeles School of Medicine. Department of Pediatrics. Los Angeles, CA, USA.
David Geffen University of California Los Angeles School of Medicine. Department of Pediatrics. Los Angeles, CA, USA.
Hospital Geral de Nova Iguaçu. Departamento de Doenças Sexualmente Transmissíveis. Nova Iguaçu, RJ, Brasil.
Universidade Federal de Minas Gerais. Departamento de Pediatria. Belo Horizonte, MG, Brasil.
San Juan City Hospital. Department of Pediatrics. San Juan, PR.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ. Brasil.
Johns Hopkins University. Division of Clinical Pharmacology. Baltimore, MD, USA.
National Institute of Child Health and Human Development (NICHD) / National Institutes of Health. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.
National Institute of Child Health and Human Development (NICHD) / National Institutes of Health. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.
National Institute of Child Health and Human Development (NICHD) / National Institutes of Health. Pediatric, Adolescent and Maternal AIDS Branch. Bethesda, MD, USA.
Westat, Inc., Rockville. MD, USA.
David Geffen University of California Los Angeles School of Medicine. Department of Pediatrics. Los Angeles, CA, USA.
Resumen en ingles
Background: The optimal neonatal antiretroviral (ARV) regimen for prevention of HIV mother-to-child transmission (MTCT) is unknown for infants born to mothers who receive no ARVs during pregnancy. Methods: As part of a protocol comparing the efficacy of 3 neonatal ARV regimens in preventing HIV-1 MTCT in neonates born to mothers who receive no prenatal treatment with ARVs, we devised a 3-dose nevirapine (NVP) regimen with the goal of maintaining the NVP plasma concentration .100 ng/mL (10 times the in vitro median inhibitory concentration of 10 ng/mL) during the first 2 weeks of life. NVP concentrations were measured in 14 newborns participating in a pharmacokinetics substudy during the second week of life and in single samples from 30 more newborns on day 10 to 14. Results: The median NVP elimination half-life was 30.2 hours (range: 17.8 to 50.3 hours). The NVP concentration remained greater than the target of 100 ng/mL in all samples collected through day 10 of life. By day 14, more than half of the newborns in the pharmacokinetic substudy had NVP levels ,100 ng/mL, although only 1 neonate had no detectable NVP. Conclusion: Although this regimen failed to meet our 100-ng/mL target, it did maintain detectable NVP concentrations in nearly all.
Palabras clave en portugues
Transmissão de mãe para filho do HIVRecém-nascido
Nevirapina
Farmacocinética
Compartir